 Joy Fulbright
Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 8 | 2022 | 120 | 2.710 |
Why?
| | Rabies Vaccines | 2 | 2016 | 2 | 1.120 |
Why?
| | Purpura, Thrombocytopenic, Idiopathic | 2 | 2016 | 3 | 1.120 |
Why?
| | Medical Oncology | 3 | 2022 | 18 | 1.090 |
Why?
| | Fertility Preservation | 2 | 2022 | 5 | 1.040 |
Why?
| | Anthracyclines | 3 | 2016 | 7 | 0.980 |
Why?
| | Heart | 2 | 2016 | 17 | 0.980 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2019 | 61 | 0.930 |
Why?
| | Antineoplastic Agents | 3 | 2019 | 57 | 0.900 |
Why?
| | Health Plan Implementation | 2 | 2020 | 10 | 0.890 |
Why?
| | Infertility | 1 | 2022 | 1 | 0.880 |
Why?
| | Primary Health Care | 2 | 2020 | 44 | 0.860 |
Why?
| | Humans | 20 | 2022 | 6797 | 0.780 |
Why?
| | Specialization | 1 | 2020 | 7 | 0.750 |
Why?
| | Heart Diseases | 3 | 2015 | 17 | 0.750 |
Why?
| | Health Personnel | 1 | 2020 | 28 | 0.740 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2011 | 114 | 0.730 |
Why?
| | Apoptosis | 2 | 2018 | 51 | 0.700 |
Why?
| | Drug Repositioning | 1 | 2018 | 3 | 0.660 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2018 | 7 | 0.650 |
Why?
| | Adolescent | 10 | 2022 | 2137 | 0.650 |
Why?
| | Male | 12 | 2021 | 3328 | 0.610 |
Why?
| | Echocardiography, Three-Dimensional | 1 | 2016 | 26 | 0.590 |
Why?
| | Magnetic Resonance Imaging | 1 | 2016 | 116 | 0.560 |
Why?
| | Acetylcysteine | 1 | 2015 | 9 | 0.560 |
Why?
| | Cardiotonic Agents | 1 | 2015 | 5 | 0.560 |
Why?
| | Child | 9 | 2022 | 3257 | 0.520 |
Why?
| | Cardiovascular Diseases | 1 | 2015 | 51 | 0.500 |
Why?
| | Xanthogranuloma, Juvenile | 1 | 2012 | 1 | 0.440 |
Why?
| | Brain Neoplasms | 1 | 2012 | 44 | 0.420 |
Why?
| | Female | 7 | 2022 | 3599 | 0.380 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2010 | 39 | 0.370 |
Why?
| | Survivors | 4 | 2016 | 17 | 0.350 |
Why?
| | Cell Line, Tumor | 2 | 2018 | 87 | 0.290 |
Why?
| | Heart Failure | 2 | 2020 | 14 | 0.290 |
Why?
| | Troponin I | 2 | 2016 | 3 | 0.280 |
Why?
| | Biomarkers | 2 | 2016 | 123 | 0.270 |
Why?
| | Animals | 2 | 2018 | 664 | 0.250 |
Why?
| | Young Adult | 3 | 2022 | 665 | 0.250 |
Why?
| | Reference Standards | 1 | 2022 | 15 | 0.220 |
Why?
| | Granular Cell Tumor | 1 | 2021 | 1 | 0.200 |
Why?
| | Lower Extremity | 1 | 2021 | 6 | 0.200 |
Why?
| | Child, Preschool | 2 | 2016 | 1503 | 0.200 |
Why?
| | Learning | 1 | 2020 | 5 | 0.190 |
Why?
| | Educational Status | 1 | 2020 | 20 | 0.190 |
Why?
| | Lymphoma, T-Cell | 1 | 2019 | 3 | 0.180 |
Why?
| | Asparaginase | 1 | 2019 | 15 | 0.180 |
Why?
| | Polyethylene Glycols | 1 | 2019 | 12 | 0.180 |
Why?
| | Desensitization, Immunologic | 1 | 2019 | 19 | 0.180 |
Why?
| | Practice Patterns, Physicians' | 1 | 2020 | 85 | 0.180 |
Why?
| | Echocardiography | 2 | 2020 | 78 | 0.170 |
Why?
| | High-Throughput Screening Assays | 1 | 2018 | 4 | 0.160 |
Why?
| | Drug Synergism | 1 | 2018 | 7 | 0.160 |
Why?
| | Small Molecule Libraries | 1 | 2018 | 5 | 0.160 |
Why?
| | Pelvic Neoplasms | 1 | 2018 | 3 | 0.160 |
Why?
| | Organs at Risk | 1 | 2018 | 3 | 0.160 |
Why?
| | Dogs | 1 | 2018 | 16 | 0.160 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2018 | 14 | 0.160 |
Why?
| | Cell Survival | 1 | 2018 | 19 | 0.160 |
Why?
| | Osteosarcoma | 1 | 2018 | 19 | 0.160 |
Why?
| | Cell Proliferation | 1 | 2018 | 56 | 0.160 |
Why?
| | Bone Neoplasms | 1 | 2018 | 23 | 0.160 |
Why?
| | Disease Models, Animal | 1 | 2018 | 74 | 0.160 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 95 | 0.160 |
Why?
| | Adult | 4 | 2020 | 1259 | 0.160 |
Why?
| | Counseling | 1 | 2018 | 60 | 0.160 |
Why?
| | Treatment Outcome | 3 | 2021 | 667 | 0.150 |
Why?
| | Peptide Fragments | 1 | 2016 | 12 | 0.150 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2016 | 6 | 0.150 |
Why?
| | Mice | 1 | 2018 | 312 | 0.150 |
Why?
| | Feasibility Studies | 1 | 2016 | 67 | 0.150 |
Why?
| | Risk Factors | 3 | 2016 | 470 | 0.150 |
Why?
| | Cardiotoxicity | 1 | 2016 | 2 | 0.140 |
Why?
| | Cardiomyopathies | 1 | 2016 | 6 | 0.140 |
Why?
| | Myocytes, Cardiac | 1 | 2015 | 1 | 0.140 |
Why?
| | Jurkat Cells | 1 | 2015 | 4 | 0.140 |
Why?
| | Reactive Oxygen Species | 1 | 2015 | 6 | 0.140 |
Why?
| | Mice, SCID | 1 | 2015 | 12 | 0.140 |
Why?
| | Oxidation-Reduction | 1 | 2015 | 11 | 0.140 |
Why?
| | Mice, Inbred BALB C | 1 | 2015 | 26 | 0.140 |
Why?
| | Leukocytes, Mononuclear | 1 | 2015 | 11 | 0.140 |
Why?
| | Antioxidants | 1 | 2015 | 5 | 0.140 |
Why?
| | Oxidative Stress | 1 | 2015 | 14 | 0.140 |
Why?
| | Leukemia | 1 | 2015 | 17 | 0.140 |
Why?
| | Cell Line | 1 | 2015 | 80 | 0.140 |
Why?
| | Acute Disease | 1 | 2015 | 71 | 0.140 |
Why?
| | Rats | 1 | 2015 | 155 | 0.130 |
Why?
| | Delivery of Health Care | 1 | 2015 | 30 | 0.130 |
Why?
| | Porphyrins | 1 | 2015 | 1 | 0.130 |
Why?
| | Dermatitis, Phototoxic | 1 | 2015 | 1 | 0.130 |
Why?
| | Troponin T | 1 | 2015 | 1 | 0.130 |
Why?
| | Phototherapy | 1 | 2015 | 2 | 0.130 |
Why?
| | Ambulatory Care Facilities | 1 | 2015 | 38 | 0.130 |
Why?
| | Benzazepines | 1 | 2015 | 6 | 0.130 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 14 | 0.130 |
Why?
| | Guidelines as Topic | 1 | 2015 | 11 | 0.130 |
Why?
| | Professionalism | 1 | 2014 | 1 | 0.130 |
Why?
| | Humanism | 1 | 2014 | 1 | 0.130 |
Why?
| | Hematology | 1 | 2014 | 3 | 0.130 |
Why?
| | Education, Medical, Graduate | 1 | 2014 | 11 | 0.130 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2012 | 4 | 0.110 |
Why?
| | Infant | 1 | 2016 | 1449 | 0.100 |
Why?
| | Endocrine System Diseases | 1 | 2011 | 1 | 0.100 |
Why?
| | Central Nervous System Neoplasms | 1 | 2011 | 5 | 0.100 |
Why?
| | Fertility | 1 | 2011 | 15 | 0.100 |
Why?
| | Growth Disorders | 1 | 2011 | 24 | 0.100 |
Why?
| | Stress, Psychological | 1 | 2011 | 37 | 0.100 |
Why?
| | Iron Chelating Agents | 1 | 2010 | 1 | 0.100 |
Why?
| | Razoxane | 1 | 2010 | 1 | 0.100 |
Why?
| | Delayed-Action Preparations | 1 | 2010 | 4 | 0.100 |
Why?
| | Drug Carriers | 1 | 2010 | 2 | 0.100 |
Why?
| | Doxorubicin | 1 | 2010 | 17 | 0.100 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 41 | 0.100 |
Why?
| | Drug Dosage Calculations | 1 | 2010 | 17 | 0.100 |
Why?
| | Disease Progression | 1 | 2010 | 105 | 0.100 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2010 | 63 | 0.090 |
Why?
| | Obesity | 1 | 2011 | 135 | 0.090 |
Why?
| | Pediatrics | 2 | 2016 | 175 | 0.060 |
Why?
| | Biopsy | 1 | 2021 | 59 | 0.050 |
Why?
| | Models, Cardiovascular | 1 | 2020 | 5 | 0.050 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 36 | 0.050 |
Why?
| | Aged, 80 and over | 1 | 2020 | 150 | 0.050 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 97 | 0.050 |
Why?
| | Aged | 1 | 2020 | 376 | 0.040 |
Why?
| | Quality of Life | 1 | 2020 | 134 | 0.040 |
Why?
| | Prognosis | 1 | 2019 | 213 | 0.040 |
Why?
| | Middle Aged | 1 | 2020 | 651 | 0.040 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2018 | 3 | 0.040 |
Why?
| | Puberty | 1 | 2018 | 5 | 0.040 |
Why?
| | Missouri | 1 | 2018 | 78 | 0.040 |
Why?
| | Radiotherapy | 1 | 2016 | 5 | 0.040 |
Why?
| | Continuity of Patient Care | 1 | 2015 | 7 | 0.030 |
Why?
| | Needs Assessment | 1 | 2015 | 21 | 0.030 |
Why?
| | Program Development | 1 | 2015 | 16 | 0.030 |
Why?
| | Program Evaluation | 1 | 2015 | 52 | 0.030 |
Why?
| | Erythroblastosis, Fetal | 1 | 2015 | 2 | 0.030 |
Why?
| | Erythrocyte Transfusion | 1 | 2015 | 2 | 0.030 |
Why?
| | Hyperbilirubinemia | 1 | 2015 | 9 | 0.030 |
Why?
| | Emergencies | 1 | 2014 | 11 | 0.030 |
Why?
| | Curriculum | 1 | 2014 | 21 | 0.030 |
Why?
| | Age Factors | 1 | 2015 | 215 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 82 | 0.030 |
Why?
| | Attitude of Health Personnel | 1 | 2014 | 50 | 0.030 |
Why?
| | Retrospective Studies | 1 | 2018 | 1332 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2014 | 297 | 0.030 |
Why?
| | United States | 1 | 2015 | 656 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2015 | 828 | 0.030 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|